Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | FSHR | P23945 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872919 | 0.97 | RAB9A (0.49) | RAB9AL3MBTL1USP2RECQLFSHR | |
| SCHEMBL5872928 | 0.80 | MEN1 (0.49) | KMT2AMEN1TDP1 | |
| SCHEMBL5872857 | 0.80 | BCL3 (0.48) | L3MBTL1KMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL5872807 | 0.80 | MEN1 (0.48) | KMT2AALDH1A1MEN1TDP1LMNA | |
| SCHEMBL5872818 | 0.79 | MEN1 (0.50) | KMT2AALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5872846 | 0.79 | KMT2A (0.49) | KMT2AALDH1A1KDM4EMEN1TDP1 | |
| SCHEMBL5872926 | 0.77 | MEN1 (0.47) | KMT2AMEN1TDP1 | |
| SCHEMBL5872804 | 0.76 | BCL3 (0.47) | KMT2AALDH1A1MEN1TDP1LMNA | |
| SCHEMBL5872816 | 0.76 | MEN1 (0.50) | KMT2AALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5872850 | 0.76 | MAP2K1 (0.56) | KMT2AMEN1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001905-B2 | Substituted diarylamines as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | BIWERSI CATHLIN (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | NRAS, MAPK6, MAPK12 | RAB9A 3021/4885L3MBTL1 2631/4885USP2 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.